Key statistics
As of last trade Avalo Therapeutics Inc (AVTX:NAQ) traded at 13.88, -33.01% below its 52-week high of 20.72, set on Dec 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 14.61 |
|---|---|
| High | 14.81 |
| Low | 13.60 |
| Bid | 13.59 |
| Offer | 13.88 |
| Previous close | 14.61 |
| Average volume | 412.59k |
|---|---|
| Shares outstanding | 18.13m |
| Free float | 17.50m |
| P/E (TTM) | -- |
| Market cap | 254.06m USD |
| EPS (TTM) | -8.79 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 15:21 GMT.
More ▼
Announcements
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
- Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
- Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
More ▼
